Talam

Quick links to important sections

Talam

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Talam

What is Talam? (Talampicillin)

Property Description
Active Ingredient Talampicillin (an ester prodrug)
Form Tablets or Capsules (Oral)
Pharmacological Class Beta-lactam Antibiotic (Semisynthetic Penicillin)
Origin / Type Synthetic Prodrug (designed for improved oral absorption)
General Purpose Treatment of Bacterial Infections
Rx Status Prescription Required

What Type of Medicine is Talam? (Definition and Classification)

Talam is a prescription medicine containing the single active ingredient, Talampicillin. It is classified as an Antibiotic and specifically belongs to the Beta-lactam antibiotic family, which makes it a semisynthetic penicillin derived from Ampicillin. Talampicillin is categorized as one of the Penicillins with extended spectrum. This compound is a single-ingredient formulation and is designated as a Prescription Required medication due to its pharmacological profile.

Talampicillin: A Prodrug Designed for Oral Use (Composition and Form)

An essential and unique feature of Talampicillin is its function as a phthalidyl ester prodrug of Ampicillin, meaning it is chemically engineered for enhanced uptake after oral administration. The medicine is supplied in solid dosage forms, typically Tablets or Capsules, which are taken by mouth. Once absorbed, the Talampicillin molecule undergoes rapid hydrolysis—a breakdown process—that releases the fully active agent, Ampicillin. This prodrug design leads to a more reliable therapeutic concentration of the anti-bacterial agent in the bloodstream compared to administering standard Ampicillin orally.

General Purpose: Combatting Bacterial Infections (High-Level Benefit)

The overall therapeutic purpose of Talam is the definitive treatment and elimination of a wide range of susceptible bacterial infections. Its mechanism ensures its action is bactericidal, meaning the drug actively destroys the harmful bacteria by interfering with the vital process of their cell wall synthesis. As an extended-spectrum penicillin, Talampicillin is generally used when a comprehensive antibiotic effect is required against both Gram-positive and Gram-negative organisms.

Regulatory References

  1. WHO Collaborating Centre for Drug Statistics Methodology

What side effects are possible with Talam?

Possible Side Effects and Safety Information

The safety profile of Talam, as defined by regulatory documents, involves side effects classified by how often they occur and which body system they affect. The information below is based strictly on authoritative government regulatory sources.

Classification Adverse Reactions (Examples)
Very Common (≥ 1/10) Nausea, Headache, Insomnia, Fatigue
Common (≥ 1/100 to < 1/10) Diarrhea, Dry Mouth, Dizziness, Increased Sweating

System-Organ Classes Involved

The documented adverse reactions primarily affect the Nervous System (e.g., Headache, Dizziness, Insomnia), Gastrointestinal Disorders (e.g., Nausea, Diarrhea, Dry Mouth), and Psychiatric Disorders (e.g., Anxiety, Agitation).

Serious Adverse Reactions

Official labeling documents severe, but infrequent, risks. These include Severe Hypersensitivity Reactions (such as Angioedema), Hematologic Toxicity (such as Agranulocytosis), and Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS). The drug is also associated with dose-dependent QT interval prolongation, which can lead to serious abnormal heart rhythms.

Safety Restrictions and Population-Specific Notes

  • Contraindications: Use is strictly prohibited in patients with pre-existing severe hepatic impairment and in those with documented hypersensitivity to the drug. It is also not recommended for patients with congenital long QT syndrome.
  • Pediatric Use: Safety and effectiveness have not been established in pediatric patients.
  • Monitoring Requirements: Routine monitoring of hepatic function tests (ALT/AST) and complete blood count (CBC) is required prior to and periodically during treatment due to potential toxicity risks. Patients should be cautioned about activities requiring mental alertness, such as driving, until they know how the medicine affects them.

Overdose and Emergency Response

Talam overdose primarily relates to high systemic levels of its active antibiotic, Ampicillin, which can lead to the severe exacerbation of documented adverse effects. Official regulatory labeling identifies several key manifestations of overexposure.

Documented presentations include pronounced gastrointestinal disturbances such as severe diarrhea, vomiting, and nausea. A major documented concern is neurological toxicity, which can result in convulsions or seizures. This risk is explicitly noted to be higher in individuals with impaired renal function due to reduced drug clearance.

The most severe documented outcomes involve life-threatening hypersensitivity (anaphylactoid) reactions and pseudomembranous colitis. Because no specific antidote is known, immediate regulatory-mandated action is essential.

Urgent Medical Attention Required: If a serious allergic reaction, seizure, collapse, or trouble breathing occurs, patients must seek immediate emergency treatment. The official procedure requires discontinuing the medication and instituting supportive measures. Management focuses on treating symptoms, and in severe cases, procedures like haemodialysis may be considered to enhance the removal of the drug from the body.

Therapeutic Uses of Talam

What Talam Treats: Main Uses and Benefits

Talam (Talampicillin) is an extended-spectrum antibiotic relevant for managing acute bacterial infections across several key domains. Its core benefit involves providing appropriate anti-bacterial support against a broad range of susceptible pathogens, which helps ease the overall symptom burden associated with the underlying illness.

The compound is indicated for treating bacterial disease and belongs to the class of Penicillins with extended spectrum.

The medication is commonly used to help with symptomatic episodes in several areas, including acute respiratory and airway infections, urinary tract infections (UTIs), and certain acute infections of the skin and soft tissues. These are conditions where symptoms cluster into disruptive patterns, requiring supportive symptom management.

“Talam is relevant when symptoms become temporarily overwhelming and short-term symptomatic assistance is appropriate.”

Treatment Domains and Patient Benefit

This medication is considered relevant in outpatient settings for addressing the systemic and localized discomfort associated with these infections. For example, in UTIs, Talam is commonly used to help with symptoms related to pain or burning during urination, or increased urgency. By providing appropriate anti-bacterial support, it may assist in easing the impact of acute manifestations on routine activities and contributes to improved day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Acute Discomfort Talam is relevant for managing symptoms related to inflammatory or irritative states caused by susceptible bacteria, helping to address localized discomfort and systemic signs of infection.

Eligibility and Restrictions for Use

Who Can and Cannot Use Talam? — Official Regulatory Information

This section outlines groups of people for whom the use of Talam (citalopram) is contraindicated, restricted, or requires special consideration, based strictly on government regulatory documents.


Contraindicated Populations (Must Not Use)

  • Patients with a known allergy or hypersensitivity to citalopram or any of the medicine’s ingredients.
  • Patients with a condition called congenital long QT syndrome or other heart rhythm abnormalities (e.g., slow or irregular heartbeat).
  • Patients who are taking, or have stopped within the past 14 days, a Monoamine Oxidase Inhibitor (MAOI), including linezolid or intravenous methylene blue.

Restricted and Limited Use

Population Category Eligibility Status Regulatory Requirement
Age (Under 18) Use Not Established Must not be given to children or adolescents under 18 years old.
Age (Over 65) Restricted/Limited A reduced maximum daily dose is required; use should be with caution.
Pregnancy/Lactation Restricted/Prohibited Generally prohibited unless risks and benefits are fully discussed and weighed by a physician. Not recommended during breastfeeding.
Hepatic/Renal Impairment Special Consideration Use requires caution and may require a lower maximum dose (e.g., for liver dysfunction or severe renal impairment).
Pre-existing Conditions Special Consideration Use with caution in patients with a history of seizures/epilepsy, glaucoma (angle-closure), bleeding/bruising disorders, or bipolar disorder/mania.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Talam is defined by specific pharmacokinetic and pharmacodynamic interactions.

A formal regulatory restriction states that the product must not be administered to patients diagnosed with Infectious Mononucleosis.


Pharmacokinetic (PK) Interactions

Substances that interfere with the body’s handling of the active agent are documented. Probenecid decreases renal tubular secretion, which results in increased and prolonged blood levels of the active component. Co-administration with high doses of Methotrexate may similarly elevate serum concentrations of that drug due to competitive inhibition of renal clearance. Furthermore, the product may reduce the efficacy of combined oral estrogen/progesterone contraceptives due to effects on gut flora. To mitigate reduced absorption, an administration-timing rule requires that the product be taken separated from food (meals).


Pharmacodynamic (PD) Interactions

Interactions that modify the clinical effect of other drugs are noted. Co-administration with Allopurinol is associated with an increased incidence of skin rash. Concurrent use with Oral Anticoagulants may cause an abnormal prolongation of prothrombin time (INR). Finally, co-administration with other bacteriostatic antibacterials (such as tetracyclines) may interfere with the bactericidal effects of the active component.

Mechanism of Action

The mechanism of Talam is mediated by its active metabolite, Ampicillin, which is released after the oral prodrug, Talampicillin, undergoes mandatory hydrolysis by esterase enzymes in the body. Ampicillin acts as an irreversible covalent inhibitor by binding specifically to Penicillin-Binding Proteins (PBPs), which are bacterial enzymes essential for cell wall synthesis. This interaction occurs at the PBP's active site, permanently deactivating its ability to catalyze the final peptidoglycan cross-linking process. The consequent formation of a structurally defective cell wall prevents the bacterial organism from withstanding its high internal osmotic pressure. This physical imbalance results in the catastrophic rupture (lysis) of the bacterial cell, producing the characteristic bactericidal physiological consequence. The mechanism is constrained by bacterial defense, such as the enzymatic inactivation of Ampicillin by beta-lactamase enzymes, and requires the bacteria to be actively synthesizing their cell wall.

Dosage and Administration Information

How Talam is Used in Practice

Talam (Talampicillin) is an extended-spectrum penicillin administered exclusively via the oral route, typically supplied as tablets or capsules. Its official usage is structured around principles that optimize the body’s absorption of the active agent, Ampicillin, and ensure the appropriate duration of the regimen.


Administration Patterns

Usage Domain Official Guideline
Route of Administration The only approved route is oral (by mouth).
Standard Dosing Adult doses are typically equivalent to 250 mg to 500 mg of the active agent, administered in divided doses.
Frequency Doses are scheduled on a multi-dose daily pattern, usually every 6 to 8 hours.
Meal Timing Administration is recommended on an empty stomach, approximately one-half to one hour before meals, to promote optimal absorption.
Course Duration The regimen must be completed entirely. The minimum duration is 48 to 72 hours after symptoms resolve, with specific infections requiring at least 10 days.

These official instructions define the required oral delivery method and link the timing of administration to food intake to maximize the systemic availability of the active drug. The process mandates a consistent schedule of divided daily doses and a strict minimum course duration. Furthermore, the official protocol requires that the dosing frequency be modified for patients with severe renal impairment to maintain the intended drug concentration. Dosing for children is also determined by body weight, following a proportional schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Talam (Talampicillin)

Evidence for Use in Urinary Tract Infections (UTIs)

Studies focused on the clinical context of urinary tract infections. Research included controlled clinical trials and comparative studies where researchers examined outcomes related to physical discomfort and systemic imbalance. The primary focus of these trials was to measure the elimination of the causative bacteria (microbiological eradication) from the urine and to assess the short-term status of patient outcomes. Findings described patterns related to the short-term clinical outcomes and the measured rates of bacterial eradication during the defined study periods. What remains uncertain is the durability of the response; long-term outcomes are not fully established or well characterized in the core regulatory research available.

Focus on the Prodrug Concept and Bioavailability

A significant portion of the research on Talam explored its unique structure as a prodrug—a compound designed for optimal absorption. Pharmacokinetic studies were conducted to monitor and measure the concentration of the active agent in the bloodstream and urine over defined time intervals. Research examined how the body absorbed the medicine and converted it into its fully active form. Studies reported that the chemical design of Talam was associated with higher peak drug levels in the blood and faster absorption compared to non-prodrug formulations of Ampicillin taken orally. While the evidence is robust regarding the pharmacokinetic advantage, these specific studies provide limited insight into long-term outcomes or clinical effectiveness in real-world settings.

What Is Still Uncertain About the Research Base

The evidence landscape for Talam relies on the historical data for its active agent, Ampicillin, and the specific pharmacokinetic advantage of the prodrug formulation. Key limitations include the reliance on foundational clinical trials conducted several decades ago. Comparative evidence is lacking for head-to-head performance against many newer-generation antibiotics used today. The research provides insight into short-term changes, but there is still a need for contemporary, large-scale studies. Certainty remains low regarding the full range of outcomes that may be observed in varied, long-term patient populations.

Key Studies & References

  1. The antibacterial efficacy and bioavailability of talampicillin in patients with urinary tract infection: a double-blind comparison with ampicillin
  2. Talampicillin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use

Frequently Asked Questions (FAQ)

Common questions about Talam (FAQ)

Q: What is the main difference between Talam and other medicines used for the same condition?

A: Official information describes Talam as a prodrug of Ampicillin, which is its key differentiating feature. This chemical design is associated with enhanced uptake of the active agent. Studies indicate that this formulation results in faster absorption and achieves higher peak levels of the medicine in the bloodstream compared to taking standard Ampicillin orally.

Q: What are the most common things people misunderstand about how Talam is supposed to be used?

A: A common point of clarification in official administration instructions relates to the need to take the medicine on an empty stomach for optimal absorption. Regulatory instructions emphasize the need to complete the entire course of treatment, even if symptoms begin to improve before the medicine is finished.

Q: Is Talam a type of controlled substance or does it have restrictions?

A: Talam is officially designated as a Prescription Required medication due to its pharmacological profile as an antibiotic. Regulatory documents classify it as a beta-lactam antibiotic, but official sources do not classify it as a federally controlled substance.

Q: Why does the packaging for Talam mention a specific type of patient group?

A: Official drug documents outline specific patient groups to ensure the medicine is used with appropriate caution. This includes populations where the medicine is restricted or requires special consideration, such as individuals over 65 who require a reduced maximum dose, or those with severe hepatic impairment.

Q: Do studies suggest Talam is useful for purposes outside of its main approved use?

A: The core regulatory research is focused primarily on the medicine’s approved uses, such as in Urinary Tract Infections (UTIs). The available research base does not establish or characterize uses outside of its approved indications.

Q: Can Talam be taken if I am already taking an over-the-counter supplement?

A: Official drug information documents known interactions with certain drugs, including some over-the-counter broad-spectrum antibacterials. However, the regulatory documents do not provide a comprehensive list or specific information regarding interactions with general vitamins, minerals, or common dietary supplements.

Q: Are there any specific foods or drinks to avoid while taking Talam?

A: Administration is officially recommended on an empty stomach to help optimize absorption of the active component. The product is recommended to be taken separated from food (meals) to mitigate reduced absorption.

Q: Is Talam considered safe for long-term use?

A: Official research indicates that long-term outcomes are not fully established or well characterized in the core regulatory research available. Periodic monitoring of hepatic function and blood counts is officially noted as necessary during treatment due to potential risks of toxicity.

Q: Can older adults or seniors use Talam without special precautions?

A: Regulatory requirements indicate that use in individuals over 65 should be approached with caution. Regulatory information indicates that a reduced maximum daily dose is necessary for this age group.

Q: Is it normal to feel slightly dizzy when first starting Talam?

A: Dizziness is a known neurological side effect, officially listed in regulatory documents as a Common adverse reaction (occurring in 1/100 to < 1/10 patients). Other central nervous system effects are also documented.

Q: How long does the effect of a single dose of Talam typically last?

A: Official administration instructions specify that dosing is typically scheduled every 6 to 8 hours in a multi-dose daily pattern. Dosing is scheduled at this frequency to help maintain the intended drug concentration.

Q: Can Talam affect my ability to drive or operate machinery?

A: Official safety restrictions advise caution regarding activities that require mental alertness, such as driving or operating machinery. This caution is in place until a person knows exactly how the medicine affects their concentration and coordination.

Q: What happens if I stop taking Talam suddenly?

A: The official instruction for Talam is that the full treatment regimen must be completed entirely. The minimum duration is 48 to 72 hours after symptoms resolve. Official instructions state that the full regimen must be completed, and stopping the medicine early is not consistent with the administration protocol.

Q: Is Talam chemically similar to any older, well-known medications?

A: Yes, Talam is chemically related to the older antibiotic, Ampicillin. Talam functions as a prodrug, meaning that once it is absorbed by the body, it is rapidly broken down to release the fully active agent, Ampicillin.

Q: Why are there different strengths or dosages of Talam available?

A: Different strengths are available because the dosing frequency must be modified for certain populations to maintain the intended concentration of the drug. For example, specific adjustments are necessary for patients with severe renal impairment, and dosing for children is determined by body weight.

Q: What are the typical age limits for prescribing Talam?

A: Official documents state that the safety and effectiveness have not been established in pediatric patients. The regulatory note indicates use is not established for children or adolescents under 18 years of age. Use in patients over 65 is restricted, requiring a reduced maximum daily dose.

Q: Is Talam known to cause drowsiness or fatigue?

A: Fatigue is officially listed as a Very Common side effect of Talam. Other central nervous system effects like Dizziness and Insomnia are also documented in the adverse reaction profile.

Q: Are headaches a temporary side effect when beginning Talam?

A: Headache is officially listed in regulatory documents as a Very Common side effect. However, official regulatory texts do not specify the duration of this effect or whether it is expected to be temporary upon beginning treatment.

Q: What is the risk of an allergic reaction to Talam?

A: A known allergy or hypersensitivity to the drug is a strict contraindication (prohibited use). The potential for Severe Hypersensitivity Reactions, such as Angioedema, is also listed in the official safety information.

Q: If Talam is prescribed, how often are patients typically monitored?

A: Official requirements address routine monitoring of certain lab values. Monitoring of hepatic function tests (ALT/AST) and complete blood count (CBC) is officially noted as necessary prior to and periodically during treatment due to potential risks.

Q: What is the relationship between Talam and long-term mood changes?

A: Official documents note adverse reactions that affect Psychiatric Disorders, including Anxiety and Agitation. However, the long-term impact on mood changes is not fully established or well characterized in the core regulatory research.

Q: Does Talam interact with birth control pills?

A: Yes, the regulatory profile states that Talam may reduce the efficacy of combined oral estrogen/progesterone contraceptives. This potential interaction is documented due to the medicine’s effects on gut flora.

Q: What makes Talam different from a placebo in clinical trials?

A: In controlled clinical trials, researchers measured that Talam resulted in the elimination of the causative bacteria (microbiological eradication) from the urine. This demonstrates a measurable therapeutic effect that distinguishes it from an inactive placebo.

Q: Are there different forms of Talam, like tablets versus liquids?

A: The official drug description states that Talam is supplied in solid dosage forms, typically as Tablets or Capsules, which are taken by mouth. Liquid forms are not mentioned in the official product information.

Q: What are the official restrictions for Talam use in children?

A: Official regulatory information clearly states that the safety and effectiveness have not been established in pediatric patients. The regulatory note indicates use is not established for children or adolescents under 18 years of age.

Q: Can Talam cause insomnia or other sleep disturbances?

A: Insomnia (difficulty sleeping) is specifically listed in official documents as a Very Common adverse reaction. Other central nervous system effects are also documented in the safety profile.

Q: Does the time of day I take Talam matter?

A: While the specific clock time is not noted as critical, regulatory instructions require the medicine to be taken at set, consistent intervals (typically every 6 to 8 hours) on an empty stomach to ensure consistent drug levels.

Q: What were the main findings of the pivotal research study on Talam?

A: The pivotal research focused heavily on Talam's unique design as a prodrug. The main findings reported that the drug was associated with higher peak drug levels in the blood and faster absorption compared to non-prodrug Ampicillin formulations.

Q: How do doctors generally decide if Talam is the right medicine?

A: Regulatory guidance describes the factors involved in selecting the medicine, which includes confirming the need for treatment of a susceptible bacterial infection and ensuring the patient does not have any official contraindications, such as documented hypersensitivity or pre-existing severe hepatic impairment.

Q: Is it true that Talam can sometimes increase anxiety initially?

A: Anxiety is listed among the documented adverse reactions that affect the Psychiatric Disorders System-Organ Class. Official data indicates that anxiety is a documented potential effect of the medicine.

Q: Does Talam have any known drug-drug interactions that are considered serious?

A: Yes, the official profile documents several interactions. Co-administration with Oral Anticoagulants is noted to cause an abnormal prolongation of prothrombin time (INR), and concurrent use with other bacteriostatic antibacterials may interfere with Talam’s bactericidal effects. These are effects related to how the body handles the medicine and how it affects other drug actions.

How should Talam be stored and disposed of?

How to Store and Dispose of Talam (Talampicillin)

Official regulatory information for Talampicillin establishes mandatory conditions to maintain the stability of this antibiotic.

Required Storage and Protection

Condition Requirement
Temperature Store below 25 °C.
Container Keep in the original container/package.
Protection Store protected from moisture.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Talam must be discarded according to local regulatory requirements for pharmaceutical waste. To protect the environment, the medicine should not be thrown away in general household rubbish or disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Talam found in:

A-Z Index: